X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

PASG

Closed

Passage Bio Inc

0.3802
-0.0201 (-5.02%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.4003
Day's Range: 0.3729 - 0.4081
Send
When Written:
 
1.04
Passage Bio Inc is a clinical-stage genetic medicines company that focuses on developing transformative therapies for rare monogenic central nervous system disorders. The company's mission is to develop and deliver life-changing gene therapies for patients with rare and devastating diseases. Passage Bio Inc was founded in 2017 and is headquartered in Philadelphia, Pennsylvania. The company's lead product candidate, PBGM01, is a gene therapy for the treatment of GM1 gangliosidosis, a rare and fatal pediatric neurodegenerative disorder. Passage Bio Inc is also developing gene therapies for the treatment of other rare genetic diseases, including Krabbe disease, frontotemporal dementia, and Niemann-Pick disease type C1. The company is backed by a strong group of investors, including OrbiMed, Frazier Healthcare Partners, Versant Ventures, and Vivo Capital.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X